SRPT Stock Recent News

Sarepta Therapeutics' most important medicine now looks even more promising. The biotech's financial results are improving substantially.

The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, was up 30% on Friday, June 21. This move came after the company secured the U.S. FDA approval for its Duchenne muscular dystrophy gene therapy – Elevidys – for all patients aged four and older.

Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Sarepta Therapeutics excels in rare disease therapies using RNA, gene editing, and gene therapies, with significant revenue growth driven by ELEVIDYS gene therapy approval. Despite missing the primary endpoint, ELEVIDYS hit key secondary endpoints, leading to FDA approval for all DMD patients ages 4 and older. Now with a label that covers roughly 80% of the DMD population, Sarepta is positioned for explosive growth in the DMD market.

Douglas Ingram, Sarepta CEO, joins 'Fast Money' to talk FDA approval of Elevidys and its impact on the company's stock.

SAN DIEGO--(BUSINESS WIRE)--Wall Street Beats is pleased to announce an investor conference call with Doug Ingram, CEO of Sarepta Therapeutics, following the landmark FDA approval expanding the label for ELEVIDYS (delandistrogene moxeparvovec-rokl) to treat Duchenne muscular dystrophy (DMD) patients aged four and above. The call will be hosted by David Maris, a six-time #1 ranked pharma analyst and partner at Wall Street Beats. Maris stated, "Sarepta's expanded label approval for ELEVIDYS is a.

Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.

Sarepta (SRPT) soars after the FDA approves expanded use of their Muscular Dystrophy treatment. Jenny Horne weighs in on this story.

Sarepta Therapeutics NASDAQ: SRPT is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving expanded FDA approval for its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys.

Sarepta Therapeutics' gene therapy received expanded US approval to include more children with a deadly muscle disease. The treatment's approval was widened for use in patients who are at least 4 years old with Duchenne muscular dystrophy.